Proton Pump Inhibitor use and Complications of Cirrhosis Are Linked with Distinct Gut Microbial Bacteriophage and Eukaryotic Viral Like Particle Signatures in Cirrhosis.
Marcela Peña RodríguezAndrew FaganMasoumeh SikaroodiPatrick M GillevetJasmohan Singh BajajPublished in: Clinical and translational gastroenterology (2023)
In cirrhosis, PPI use has a gut microbial VLP phage signature that is different from that in HE and ascites, and VLP changes are linked with hospitalizations over 6 months, independent of clinical biomarkers. Eucaryotic virus patterns were consistent across PPI use, HE, and ascites, indicating a relationship with the progression of cirrhosis. PPIs alone showed modest VLP changes with withdrawal or initiation. Distinct phage and eukaryotic viral patterns are associated with the use of PPIs in cirrhosis.